Scholarlink

<p>Psoriasis is an immune-mediated skin condition that impacts approximately 3% of the United States population, with limited adjunctive therapy options. This study investigates the effects of light emitting diode red light (LED-RL) as a potential adjunct. Using in vitro keratinocytes, three-dimensional (3D) recapitulated skin models, and a mouse model, LED-RL’s impact on keratinocyte proliferation and epidermal thickness was assessed. Our findings show that LED-RL significantly reduced keratinocyte proliferation without inducing apoptosis, likely through cell cycle modulation and decreased phosphorylation of STAT3, a pathway critical to psoriasis pathogenesis. In the 3D skin models, LED-RL at a dose of 640&#xa0;J/cm<sup>2</sup> reduced epidermal thickness in IL-22-stimulated samples. In mouse models, a daily dose of 1280&#xa0;J/cm<sup>2</sup> decreased epidermal thickness when co-administered and administered following the development of a psoriasiform phenotype with imiquimod. These results suggest LED-RL may offer an efficacious and cost-effective alternative to existing therapies for mild to moderate psoriasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Light-emitting diode red light attenuates epidermal thickening and keratinocyte proliferation in psoriasis models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Evan Austin,
  • Eugene Koo,
  • Margaret Kabakova,
  • Marc Cohen,
  • Alana Kurtti,
  • Andrew Mamalis,
  • Emanuel Maverakis,
  • Roslyn Rivkah Isseroff,
  • Jared Jagdeo

摘要

Psoriasis is an immune-mediated skin condition that impacts approximately 3% of the United States population, with limited adjunctive therapy options. This study investigates the effects of light emitting diode red light (LED-RL) as a potential adjunct. Using in vitro keratinocytes, three-dimensional (3D) recapitulated skin models, and a mouse model, LED-RL’s impact on keratinocyte proliferation and epidermal thickness was assessed. Our findings show that LED-RL significantly reduced keratinocyte proliferation without inducing apoptosis, likely through cell cycle modulation and decreased phosphorylation of STAT3, a pathway critical to psoriasis pathogenesis. In the 3D skin models, LED-RL at a dose of 640 J/cm2 reduced epidermal thickness in IL-22-stimulated samples. In mouse models, a daily dose of 1280 J/cm2 decreased epidermal thickness when co-administered and administered following the development of a psoriasiform phenotype with imiquimod. These results suggest LED-RL may offer an efficacious and cost-effective alternative to existing therapies for mild to moderate psoriasis.